Actively Recruiting
Long-Term Safety and Tolerability of Rimegepant for Acute Migraine Treatment in Children and Adolescents Aged 6 to Under 18 Years
Led by Pfizer · Updated on 2026-10-27
600
Participants Needed
124
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.
CONDITIONS
Brief Title
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Research Team
P
Pfizer Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here